| Nov 13 |
Mural Oncology plc GAAP EPS of -$1.87 beats by $0.03
|
| Nov 13 |
Mural Oncology Announces Third Quarter 2024 Financial Results and Provides Update on Pipeline Progress
|
| Nov 11 |
Mural Oncology to Participate in Two Upcoming Investor Conferences
|
| Oct 7 |
Mural Oncology to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
|
| Sep 26 |
Mural Oncology’s First Virtual Investor Day to Highlight Late-Stage Clinical Progress
|
| Sep 23 |
Mural Oncology Strengthens Board of Directors with the Appointment of Sachiyo Minegishi
|
| Sep 4 |
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
| Sep 4 |
We Think Mural Oncology (NASDAQ:MURA) Needs To Drive Business Growth Carefully
|
| Aug 27 |
Mural Oncology to Present at Two Upcoming Investor Conferences
|
| Jul 31 |
Mural Oncology Appoints Veteran Business Development Executive George Golumbeski, Ph.D., to its Board of Directors
|
